To counter unmet market needs and provide better treatment choices for AL Amyloidosis, several players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the coming years, thereby driving market growth.
Currently, the leading companies in the AL Amyloidosis Market include Janssen, Prothena, Alexion Pharmaceuticals, Oncopeptides AB, Bristol-Myers Squibb, Alnylam Pharmaceuticals, Attralus, Neurimmune AG, Ionis Pharmaceuticals, Akcea, and others. Some of the drugs in the pipeline for AL Amyloidosis include Daratumumab (Janssen Pharmaceuticals), Melflufen (Oncopeptides AB), Elotuzumab (Bristol-Myers Squibb), Birtamimab (Prothena), among others.
DelveInsight's "AL Amyloidosis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the AL Amyloidosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The AL Amyloidosis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
AL Amyloidosis: An Overview
Amyloidosis is a rare disease resulting from abnormal protein deposits, called amyloid, in various tissues of the body. Depending on the structure of the particular amyloid, the protein can accumulate in an isolated tissue or be widespread, affecting numerous organs and tissues. There are over 30 different amyloid proteins. Each amyloid protein is arranged in a structure called a fibril—a low molecular weight protein derived from precursor proteins. Amyloid fibrils can float in the blood plasma and deposit into tissues of the body.
AL Amyloidosis Market Key Facts
-
In 2021, the total incident cases of AL Amyloidosis were the highest in the US, with nearly 4,500 cases, and the lowest cases were registered in Spain, with approximately 400 cases.
-
In 2021, Japan accounted for more than 500 incident cases of AL Amyloidosis.
-
Among EU5 countries, Germany had the highest number of incident cases of AL Amyloidosis (>900 cases) in 2021.
-
Spain had the lowest incident population of AL Amyloidosis (~400 cases) in 2021.
-
AL Amyloidosis is slightly more prominent in males as compared to females. The US had about 2,500 males compared to ~2,100 females suffering from AL Amyloidosis in 2021.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted AL Amyloidosis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the AL Amyloidosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
AL Amyloidosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the AL Amyloidosis Epidemiology Segmented by -
-
Total Incident Cases of AL Amyloidosis (2019–2032)
-
Gender-specific Cases of AL Amyloidosis (2019–2032)
-
Age-specific Cases of AL Amyloidosis (2019–2032)
AL Amyloidosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the AL Amyloidosis market or expected to be launched during the study period. The analysis covers the AL Amyloidosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the AL Amyloidosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the AL Amyloidosis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/al-amyloidosis-market
AL Amyloidosis Therapeutics Analysis
The Leading Companies in the AL Amyloidosis Therapeutics Market Include:
-
Acrotech Biopharma
-
Alexion Pharmaceuticals
-
Astellas Pharma GmbH
-
Bristol-Myers Squibb
-
Caelum Biosciences
-
Celgene Corporation
-
GlaxoSmithKline
-
Janssen Pharmaceutical
-
Merck & Co
-
Oncopeptides AB
-
Prothena
-
Sanofi
-
Sorrento Therapeutics
-
Takeda
And Many Others
AL Amyloidosis Drugs Covered in the Report Include:
-
Belantamab mafodotin: GlaxoSmithKline
-
Birtamimab: Prothena
-
CAEL-101: Alexion Pharmaceuticals
-
Daratumumab: Janssen Pharmaceutical
-
Elotuzumab: Bristol-Myers Squibb
-
Evomela: Acrotech Biopharma
-
Ixazomib: Takeda
-
Melflufen: Oncopeptides AB
-
Pomalidomide: Celgene Corporation
-
STI 6129: Sorrento Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/al-amyloidosis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. AL Amyloidosis Competitive Intelligence Analysis
4. AL Amyloidosis Market Overview at a Glance
5. AL Amyloidosis Disease Background and Overview
6. AL Amyloidosis Patient Journey
7. AL Amyloidosis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. AL Amyloidosis Treatment Algorithm, Current Treatment, and Medical Practices
9. AL Amyloidosis Unmet Needs
10. Key Endpoints of AL Amyloidosis Treatment
11. AL Amyloidosis Marketed Products
12. AL Amyloidosis Emerging Drugs and Latest Therapeutic Advances
13. AL Amyloidosis Seven Major Market Analysis
14. Attribute Analysis
15. AL Amyloidosis Market Outlook (In US, EU5, and Japan)
16. AL Amyloidosis Access and Reimbursement Overview
17. KOL Views on the AL Amyloidosis Market
18. AL Amyloidosis Market Drivers
19. AL Amyloidosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/al-amyloidosis-market
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
